Yki-Jarvinen H, Thiazolidinediones. N Engl J Med 2004; 351:1106-18.
 Nissen SE, Wolski K. Effect of rosiglita-zone on the risk of myocardial infarction and death from car-diovascular causes. N Engl J Med 2007; 356:2457-71.
 Hersh AL, Ste MJ, Stafford RS. National use of posmenopausal hormone thrapy. Annual trends and re-sponse to recent evidence. JAMA 2004; 291:47-53.
 Majumdar SR, Almasi EA, Stafford RS. Pro-motion and prescribing of hormone therapy after report of harm by the women’s health initiative. JAMA 2004; 292:1983-88.
 Hsiao F-Y, Tsai Y-W, Huang W-F. Changes in physician’s practice of prescribing cyclooxy-genase-2 inhibitor after market withdrawal of rofecoxib: a ret-rospective study of physician-patient pairs in Taiwan. Clin Ther +2009; 31:2618-27.
 Geraghty EM, Balsbaugh T, Nuovo J, Tandon S. Using geographic information systems (GIS) to assess outcome disparities in patients with type 2 diabetes and hyperlipidemia. J Am Board Fam Med 2010; 23:88-96.
 Majumdar SR, Inui TS, Gurwitz JH, et al. In-fluence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocar-dial infarction. J Gen Intern Med 2001; 16:351-59.
 Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care 2010; 33:823-5.
 Faber A, Bouvy ML, Loskamp L, et al. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005; 60: 641-7.
 Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patient’s requests for direct-to-consumer advertised antidepressants. A randomized controlled trial. JAMA 2005; 293:1995-2002.
 Garfield E. The history and meaning of the journal impact factor. JAMA 2006; 295:90-3.
 Greene JA, Kesselheim AS. Pharmaceutical marketing and the new social media. N Engl J Med 2010; 363:2087- 9.
 Shah ND, Montori VM, Krumholz HM, et al. Responding to an FDA warning-Geographic variation in the use of rosiglitazone. N Engl J Med 2010;363:2081-4.